Nano-sized, tumor-targeting particles induced self-destruction of cancer cells in preclinical studies.

A new twist on a decades-old anticancer strategy has demonstrated significant potential against various cancer types in a preclinical study conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania. The innovative method employs small extracellular vesicles (sEVs)—tiny capsules engineered from human cells—offering a promising new avenue for immunotherapy. This approach is now advancing toward further development and testing.